Marlana M. Orloff, MD, of Thomas Jefferson University Hospital, reviews primary results from the OptimUM-02 trial, which investigated the doublet of darovasertib plus crizotinib vs investgator’s choice for first-line therapy among patients with HLA-A2–negative metastatic uveal melanoma (Abstract LBA9503).
John V. Heymach, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses results from the primary analysis of the multinational phase III WU-KONG28 trial, which looked at sunvozertinib monotherapy vs platinum-based therapy as first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) and EGFR exon 20 insertions (Abstract LBA8500).
Shilpa Gupta, MD, of Taussig Cancer Institute, discusses findings from the phase III MAIN-CAV study (Alliance A032001) of maintenance cabozantinib and avelumab vs avelumab after first-line platinum-based chemotherapy in patients with locally advanced/metastatic urothelial cancer (Abstract 4514).
Walter Weber, MD, of University Hospital Basel, presents data from the international randomized phase III PREPEC trial (OPBC-02), which found prepectoral implant-based breast reconstruction (IBBR) significantly and relevantly improved long-term quality of life—at the cost of a higher risk of loss or replacement of expander or implant—compared to subpectoral IBBR (Abstract 504).
Suneel Kamath, MD, of Cleveland Clinic, discusses a study that found tissue tumor mutation burden (TMB) was a stronger predictor of immunotherapy outcomes than blood-based circulating tumor DNA testing, with high tissue TMB associated with a longer time to treatment failure (Abstract 2580).
Jana de Boniface, MD, PhD, of Capio Saint Göran's Hospital and Karolinska Institutet, reviews overall survival and patient-reported arm morbidity findings from the SENOMAC trial, which sought to determine if patients with breast cancer and sentinel lymph node macrometastases could omit complete axillary dissection (Abstract LBA503).
